×

MPL cDNA ORF clone, Homo sapiens(Human)

Gene Symbol MPL
Entrez Gene ID 4352
Full Name MPL proto-oncogene, thrombopoietin receptor
Synonyms C-MPL,CD110,MPLV,THCYT2,TPOR
General protein information
Preferred Names

MPL proto-oncogene, thrombopoietin receptor

Names

thrombopoietin receptor
TPO-R
myeloproliferative leukemia protein
myeloproliferative leukemia virus oncogene
proto-oncogene c-Mpl

Gene Type protein-coding
Organism Homo sapiens(Human)
Genome

1

1p34.2

Summary In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated. [provided by RefSeq, Jul 2008].
Disorder MIM:

159530

Disorder Html: Thrombocytopenia, congenital amegakaryocytic, 604498 (3);

mRNA and Protein(s)

mRNA Protein Name
NM_005373.2 NP_005364.1 thrombopoietin receptor precursor
XM_017001320.1 XP_016856809.1 thrombopoietin receptor isoform X1



Mus musculus (house mouse) Mpl NP_001116421.1
Gallus gallus (chicken) MPL NP_001001782.1
Macaca mulatta (rhesus monkey) MPL XP_002801551.1
Bos taurus (cattle) MPL NP_001179592.1
Rattus norvegicus (Norway rat) Mpl XP_345573.5
Danio rerio (zebrafish) mpl NP_001003858.1
Homo sapiens (human) MPL NP_005364.1


Related articles in PubMed

FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
Ebrahim EK, Assem MM, Amin AI, Kamel MM, El Meligui YM, Metwally AM
Annals of clinical and laboratory science46(6)592-600(2016 Dec)

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A
Cancer discovery6(4)368-81(2016 Apr)

The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC, Chang CS, Lin SF
Experimental hematology35(11)1704-7(2007 Nov)

Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
Norton A, Fisher C, Liu H, Wen Q, Mundschau G, Fuster JL, Hasle H, Zeller B, Webb DK, O'Marcaigh A, Sorrell A, Hilden J, Gamis A, Crispino JD, Vyas P
Blood110(3)1077-9(2007 Aug)

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, Bosi A, Barosi G, Vannucchi AM, ,
British journal of haematology137(3)244-7(2007 May)

GeneRIFs: Gene References Into Functions What's a GeneRIF?

Coexisting mutations of the JAK2, CALR, and MPL genes in myeloproliferative neoplasms suggest that CALR and MPL should be analyzed not only in JAK2-negative patients but also in low V617F mutation patients.
Title: Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.

Normal FLT3 and negative expression of CD34 and cMPL may predict a longer overall survival in aute myeloid leukemia.
Title: FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.

these results demonstrate that MPL P106L is a receptor with an incomplete defect in trafficking.
Title: An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L.

In essential thrombocythemia, MPL mutations might be associated with a higher risk of fibrotic transformation and the presence of JAK2/MPL mutations with higher risk of thrombosis.
Title: Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.

we show that the positive charge of the CALR mutant C-terminus is necessary to transform hematopoietic cells by enabling binding between mutant CALR and the thrombopoietin receptor MPL.
Title: Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

The following MPL gene cDNA ORF clone sequences were retrieved from the NCBI Reference Sequence Database (RefSeq). These sequences represent the protein coding region of the MPL cDNA ORF which is encoded by the open reading frame (ORF) sequence. ORF sequences can be delivered in our standard vector, pcDNA3.1+/C-(K)DYK or the vector of your choice as an expression/transfection-ready ORF clone. Not the clone you want? Click here to find your clone.

Online Only Promotion

Up to 50% OFF! Starting
from $49/clone

Free DYK Tag Antibody

***CloneID RefSeq Accession Definition **Vector *Turnaround time Price (USD) Select
OHu28553
NM_005373.2
Latest version!
Homo sapiens MPL proto-oncogene, thrombopoietin receptor (MPL), mRNA. pcDNA3.1+/C-(K)DYK or customized vector
in pcDNA3.1+/C-(K)DYK
$49.50-$69.30
$99.00
OHu87426 XM_017001320.1
Latest version!
Homo sapiens MPL proto-oncogene, thrombopoietin receptor (MPL), transcript variant X1, mRNA. pcDNA3.1+/C-(K)DYK or customized vector 14-16 $391.30
$559.00

ORF Online Only Promotion

Next-day Shipping ORF Clones ( in default vector with tag)
1 Clone 30% OFF
2-4 Clone 40% OFF
5 or more Clone 50% OFF
All Other ORF Clones
30% OFF

*Business Day

** You may select a custom vector to replace pcDNA3.1+/C-(K)DYK after clone is added to cart.

** GenScript guarantees 100% sequence accuracy of all synthetic DNA constructs we deliver, but we do not guarantee protein expression in your experimental system. Protein expression is influenced by many factors that may vary between experiments or laboratories. In addition, please pay attention to the signal peptide, propeptide and transit peptide in target ORF, which may affect the choice of vector (N/C terminal tag vector).

***One clone ID might be correlated to multiple accession numbers, which share the same CDS sequence.


CloneID OHu28553
Clone ID Related Accession (Same CDS sequence) NM_005373.2
Accession Version NM_005373.2 Latest version! Documents for ORF clone product in dufault vector
Sequence Information ORF Nucleotide Sequence (Length: 1908bp)
Protein sequence
SNP
Vector pcDNA3.1+/C-(K)DYK or customized vector User Manual
Clone information Clone Map MSDS
Tag on pcDNA3.1+/C-(K)DYK C terminal DYKDDDDK tags COA
ORF Insert Method CloneEZ® Seamless cloning technology
Insert Structure linear
Update Date 2017-05-07
Organism Homo sapiens(Human)
Product thrombopoietin receptor precursor
Comment REVIEWED REFSEQ: This record has been curated by NCBI staff. The reference sequence was derived from AL139289.6 and M90102.1. This sequence is a reference standard in the RefSeqGene project. On Apr 4, 2008 this sequence version replaced NM_005373.1. Sequence Note: This RefSeq record was created from transcript and genomic sequence data because no single transcript was available for the full length of the gene. The extent of this transcript is supported by transcript alignments. Publication Note: This RefSeq record includes a subset of the publications that are available for this gene. Please see the Gene record to access additional publications. ##Evidence-Data-START## Transcript exon combination :: M90102.1 [ECO:0000332] RNAseq introns :: mixed/partial sample support SAMEA1965299, SAMEA1968189 [ECO:0000350] ##Evidence-Data-END## COMPLETENESS: complete on the 3' end.

1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
ATGCCCTCCT GGGCCCTCTT CATGGTCACC TCCTGCCTCC TCCTGGCCCC TCAAAACCTG 
GCCCAAGTCA GCAGCCAAGA TGTCTCCTTG CTGGCATCAG ACTCAGAGCC CCTGAAGTGT
TTCTCCCGAA CATTTGAGGA CCTCACTTGC TTCTGGGATG AGGAAGAGGC AGCGCCCAGT
GGGACATACC AGCTGCTGTA TGCCTACCCG CGGGAGAAGC CCCGTGCTTG CCCCCTGAGT
TCCCAGAGCA TGCCCCACTT TGGAACCCGA TACGTGTGCC AGTTTCCAGA CCAGGAGGAA
GTGCGTCTCT TCTTTCCGCT GCACCTCTGG GTGAAGAATG TGTTCCTAAA CCAGACTCGG
ACTCAGCGAG TCCTCTTTGT GGACAGTGTA GGCCTGCCGG CTCCCCCCAG TATCATCAAG
GCCATGGGTG GGAGCCAGCC AGGGGAACTT CAGATCAGCT GGGAGGAGCC AGCTCCAGAA
ATCAGTGATT TCCTGAGGTA CGAACTCCGC TATGGCCCCA GAGATCCCAA GAACTCCACT
GGTCCCACGG TCATACAGCT GATTGCCACA GAAACCTGCT GCCCTGCTCT GCAGAGGCCT
CACTCAGCCT CTGCTCTGGA CCAGTCTCCA TGTGCTCAGC CCACAATGCC CTGGCAAGAT
GGACCAAAGC AGACCTCCCC AAGTAGAGAA GCTTCAGCTC TGACAGCAGA GGGTGGAAGC
TGCCTCATCT CAGGACTCCA GCCTGGCAAC TCCTACTGGC TGCAGCTGCG CAGCGAACCT
GATGGGATCT CCCTCGGTGG CTCCTGGGGA TCCTGGTCCC TCCCTGTGAC TGTGGACCTG
CCTGGAGATG CAGTGGCACT TGGACTGCAA TGCTTTACCT TGGACCTGAA GAATGTTACC
TGTCAATGGC AGCAACAGGA CCATGCTAGC TCCCAAGGCT TCTTCTACCA CAGCAGGGCA
CGGTGCTGCC CCAGAGACAG GTACCCCATC TGGGAGAACT GCGAAGAGGA AGAGAAAACA
AATCCAGGAC TACAGACCCC ACAGTTCTCT CGCTGCCACT TCAAGTCACG AAATGACAGC
ATTATTCACA TCCTTGTGGA GGTGACCACA GCCCCGGGTA CTGTTCACAG CTACCTGGGC
TCCCCTTTCT GGATCCACCA GGCTGTGCGC CTCCCCACCC CAAACTTGCA CTGGAGGGAG
ATCTCCAGTG GGCATCTGGA ATTGGAGTGG CAGCACCCAT CGTCCTGGGC AGCCCAAGAG
ACCTGTTATC AACTCCGATA CACAGGAGAA GGCCATCAGG ACTGGAAGGT GCTGGAGCCG
CCTCTCGGGG CCCGAGGAGG GACCCTGGAG CTGCGCCCGC GATCTCGCTA CCGTTTACAG
CTGCGCGCCA GGCTCAACGG CCCCACCTAC CAAGGTCCCT GGAGCTCGTG GTCGGACCCA
ACTAGGGTGG AGACCGCCAC CGAGACCGCC TGGATCTCCT TGGTGACCGC TCTGCATCTA
GTGCTGGGCC TCAGCGCCGT CCTGGGCCTG CTGCTGCTGA GGTGGCAGTT TCCTGCACAC
TACAGGAGAC TGAGGCATGC CCTGTGGCCC TCACTTCCAG ACCTGCACCG GGTCCTAGGC
CAGTACCTTA GGGACACTGC AGCCCTGAGC CCGCCCAAGG CCACAGTCTC AGATACCTGT
GAAGAAGTGG AACCCAGCCT CCTTGAAATC CTCCCCAAGT CCTCAGAGAG GACTCCTTTG
CCCCTGTGTT CCTCCCAGGC CCAGATGGAC TACCGAAGAT TGCAGCCTTC TTGCCTGGGG
ACCATGCCCC TGTCTGTGTG CCCACCCATG GCTGAGTCAG GGTCCTGCTG TACCACCCAC
ATTGCCAACC ATTCCTACCT ACCACTAAGC TATTGGCAGC AGCCTTGA

The stop codons will be deleted if pcDNA3.1+/C-(K)DYK vector is selected.

RefSeq NP_005364.1
CDS46..1953
Misc Feature(1)19..21
Exon (1)1..124
Translation

Target ORF information:

RefSeq Version NM_005373.2
Organism Homo sapiens(Human)
Definition Homo sapiens MPL proto-oncogene, thrombopoietin receptor (MPL), mRNA.

Target ORF information:

Epitope DYKDDDDK
Bacterial selection AMPR
Mammalian selection NeoR
Vector pcDNA3.1+/C-(K)DYK
NM_005373.2

ORF Insert Sequence:

1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
ATGCCCTCCT GGGCCCTCTT CATGGTCACC TCCTGCCTCC TCCTGGCCCC TCAAAACCTG 
GCCCAAGTCA GCAGCCAAGA TGTCTCCTTG CTGGCATCAG ACTCAGAGCC CCTGAAGTGT
TTCTCCCGAA CATTTGAGGA CCTCACTTGC TTCTGGGATG AGGAAGAGGC AGCGCCCAGT
GGGACATACC AGCTGCTGTA TGCCTACCCG CGGGAGAAGC CCCGTGCTTG CCCCCTGAGT
TCCCAGAGCA TGCCCCACTT TGGAACCCGA TACGTGTGCC AGTTTCCAGA CCAGGAGGAA
GTGCGTCTCT TCTTTCCGCT GCACCTCTGG GTGAAGAATG TGTTCCTAAA CCAGACTCGG
ACTCAGCGAG TCCTCTTTGT GGACAGTGTA GGCCTGCCGG CTCCCCCCAG TATCATCAAG
GCCATGGGTG GGAGCCAGCC AGGGGAACTT CAGATCAGCT GGGAGGAGCC AGCTCCAGAA
ATCAGTGATT TCCTGAGGTA CGAACTCCGC TATGGCCCCA GAGATCCCAA GAACTCCACT
GGTCCCACGG TCATACAGCT GATTGCCACA GAAACCTGCT GCCCTGCTCT GCAGAGGCCT
CACTCAGCCT CTGCTCTGGA CCAGTCTCCA TGTGCTCAGC CCACAATGCC CTGGCAAGAT
GGACCAAAGC AGACCTCCCC AAGTAGAGAA GCTTCAGCTC TGACAGCAGA GGGTGGAAGC
TGCCTCATCT CAGGACTCCA GCCTGGCAAC TCCTACTGGC TGCAGCTGCG CAGCGAACCT
GATGGGATCT CCCTCGGTGG CTCCTGGGGA TCCTGGTCCC TCCCTGTGAC TGTGGACCTG
CCTGGAGATG CAGTGGCACT TGGACTGCAA TGCTTTACCT TGGACCTGAA GAATGTTACC
TGTCAATGGC AGCAACAGGA CCATGCTAGC TCCCAAGGCT TCTTCTACCA CAGCAGGGCA
CGGTGCTGCC CCAGAGACAG GTACCCCATC TGGGAGAACT GCGAAGAGGA AGAGAAAACA
AATCCAGGAC TACAGACCCC ACAGTTCTCT CGCTGCCACT TCAAGTCACG AAATGACAGC
ATTATTCACA TCCTTGTGGA GGTGACCACA GCCCCGGGTA CTGTTCACAG CTACCTGGGC
TCCCCTTTCT GGATCCACCA GGCTGTGCGC CTCCCCACCC CAAACTTGCA CTGGAGGGAG
ATCTCCAGTG GGCATCTGGA ATTGGAGTGG CAGCACCCAT CGTCCTGGGC AGCCCAAGAG
ACCTGTTATC AACTCCGATA CACAGGAGAA GGCCATCAGG ACTGGAAGGT GCTGGAGCCG
CCTCTCGGGG CCCGAGGAGG GACCCTGGAG CTGCGCCCGC GATCTCGCTA CCGTTTACAG
CTGCGCGCCA GGCTCAACGG CCCCACCTAC CAAGGTCCCT GGAGCTCGTG GTCGGACCCA
ACTAGGGTGG AGACCGCCAC CGAGACCGCC TGGATCTCCT TGGTGACCGC TCTGCATCTA
GTGCTGGGCC TCAGCGCCGT CCTGGGCCTG CTGCTGCTGA GGTGGCAGTT TCCTGCACAC
TACAGGAGAC TGAGGCATGC CCTGTGGCCC TCACTTCCAG ACCTGCACCG GGTCCTAGGC
CAGTACCTTA GGGACACTGC AGCCCTGAGC CCGCCCAAGG CCACAGTCTC AGATACCTGT
GAAGAAGTGG AACCCAGCCT CCTTGAAATC CTCCCCAAGT CCTCAGAGAG GACTCCTTTG
CCCCTGTGTT CCTCCCAGGC CCAGATGGAC TACCGAAGAT TGCAGCCTTC TTGCCTGGGG
ACCATGCCCC TGTCTGTGTG CCCACCCATG GCTGAGTCAG GGTCCTGCTG TACCACCCAC
ATTGCCAACC ATTCCTACCT ACCACTAAGC TATTGGCAGC AGCCTTGA

The stop codons will be deleted if pcDNA3.1+/C-(K)DYK vector is selected.

CloneID OHu87426
Clone ID Related Accession (Same CDS sequence) XM_017001320.1
Accession Version XM_017001320.1 Latest version! Documents for ORF clone product in dufault vector
Sequence Information ORF Nucleotide Sequence (Length: 2079bp)
Protein sequence
SNP
Vector pcDNA3.1+/C-(K)DYK or customized vector User Manual
Clone information Clone Map MSDS
Tag on pcDNA3.1+/C-(K)DYK C terminal DYKDDDDK tags
ORF Insert Method CloneEZ® Seamless cloning technology
Insert Structure linear
Update Date 2016-06-06
Organism Homo sapiens(Human)
Product thrombopoietin receptor isoform X1
Comment MODEL REFSEQ: This record is predicted by automated computational analysis. This record is derived from a genomic sequence (NC_000001.11) annotated using gene prediction method: Gnomon, supported by mRNA evidence. Also see: Documentation of NCBI's Annotation Process ##Genome-Annotation-Data-START## Annotation Provider :: NCBI Annotation Status :: Full annotation Annotation Version :: Homo sapiens Annotation Release 108 Annotation Pipeline :: NCBI eukaryotic genome annotation pipeline Annotation Software Version :: 7.0 Annotation Method :: Best-placed RefSeq; Gnomon Features Annotated :: Gene; mRNA; CDS; ncRNA ##Genome-Annotation-Data-END##

1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
1921
1981
2041
ATGCCCTCCT GGGCCCTCTT CATGGTCACC TCCTGCCTCC TCCTGGCCCC TCAAAACCTG 
GCCCAAGTCA GCAGCCAAGG TGAGGTGCAC AGAGGGTGGA GATCACCTAT GCCCAGGAAG
AGGGAGCCCT GGGAGGTGAT GCAGGGCCCC GGGAGGGGAG GTAGAGTAAG AGGCTCTCCT
GCTGGTCCCC TCCCCTTCCA CATAAACATG CCTGGGAGGA CCCAGGGCCA ACTCACCAGC
TGTTCCTTAG ATGTCTCCTT GCTGGCATCA GACTCAGAGC CCCTGAAGTG TTTCTCCCGA
ACATTTGAGG ACCTCACTTG CTTCTGGGAT GAGGAAGAGG CAGCGCCCAG TGGGACATAC
CAGCTGCTGT ATGCCTACCC GCGGGAGAAG CCCCGTGCTT GCCCCCTGAG TTCCCAGAGC
ATGCCCCACT TTGGAACCCG ATACGTGTGC CAGTTTCCAG ACCAGGAGGA AGTGCGTCTC
TTCTTTCCGC TGCACCTCTG GGTGAAGAAT GTGTTCCTAA ACCAGACTCG GACTCAGCGA
GTCCTCTTTG TGGACAGTGT AGGCCTGCCG GCTCCCCCCA GTATCATCAA GGCCATGGGT
GGGAGCCAGC CAGGGGAACT TCAGATCAGC TGGGAGGAGC CAGCTCCAGA AATCAGTGAT
TTCCTGAGGT ACGAACTCCG CTATGGCCCC AGAGATCCCA AGAACTCCAC TGGTCCCACG
GTCATACAGC TGATTGCCAC AGAAACCTGC TGCCCTGCTC TGCAGAGGCC TCACTCAGCC
TCTGCTCTGG ACCAGTCTCC ATGTGCTCAG CCCACAATGC CCTGGCAAGA TGGACCAAAG
CAGACCTCCC CAAGTAGAGA AGCTTCAGCT CTGACAGCAG AGGGTGGAAG CTGCCTCATC
TCAGGACTCC AGCCTGGCAA CTCCTACTGG CTGCAGCTGC GCAGCGAACC TGATGGGATC
TCCCTCGGTG GCTCCTGGGG ATCCTGGTCC CTCCCTGTGA CTGTGGACCT GCCTGGAGAT
GCAGTGGCAC TTGGACTGCA ATGCTTTACC TTGGACCTGA AGAATGTTAC CTGTCAATGG
CAGCAACAGG ACCATGCTAG CTCCCAAGGC TTCTTCTACC ACAGCAGGGC ACGGTGCTGC
CCCAGAGACA GGTACCCCAT CTGGGAGAAC TGCGAAGAGG AAGAGAAAAC AAATCCAGGA
CTACAGACCC CACAGTTCTC TCGCTGCCAC TTCAAGTCAC GAAATGACAG CATTATTCAC
ATCCTTGTGG AGGTGACCAC AGCCCCGGGT ACTGTTCACA GCTACCTGGG CTCCCCTTTC
TGGATCCACC AGGCTGTGCG CCTCCCCACC CCAAACTTGC ACTGGAGGGA GATCTCCAGT
GGGCATCTGG AATTGGAGTG GCAGCACCCA TCGTCCTGGG CAGCCCAAGA GACCTGTTAT
CAACTCCGAT ACACAGGAGA AGGCCATCAG GACTGGAAGG TGCTGGAGCC GCCTCTCGGG
GCCCGAGGAG GGACCCTGGA GCTGCGCCCG CGATCTCGCT ACCGTTTACA GCTGCGCGCC
AGGCTCAACG GCCCCACCTA CCAAGGTCCC TGGAGCTCGT GGTCGGACCC AACTAGGGTG
GAGACCGCCA CCGAGACCGC CTGGATCTCC TTGGTGACCG CTCTGCATCT AGTGCTGGGC
CTCAGCGCCG TCCTGGGCCT GCTGCTGCTG AGGTGGCAGT TTCCTGCACA CTACAGGAGA
CTGAGGCATG CCCTGTGGCC CTCACTTCCA GACCTGCACC GGGTCCTAGG CCAGTACCTT
AGGGACACTG CAGCCCTGAG CCCGCCCAAG GCCACAGTCT CAGATACCTG TGAAGAAGTG
GAACCCAGCC TCCTTGAAAT CCTCCCCAAG TCCTCAGAGA GGACTCCTTT GCCCCTGTGT
TCCTCCCAGG CCCAGATGGA CTACCGAAGA TTGCAGCCTT CTTGCCTGGG GACCATGCCC
CTGTCTGTGT GCCCACCCAT GGCTGAGTCA GGGTCCTGCT GTACCACCCA CATTGCCAAC
CATTCCTACC TACCACTAAG CTATTGGCAG CAGCCTTGA

The stop codons will be deleted if pcDNA3.1+/C-(K)DYK vector is selected.

RefSeq XP_016856809.1
CDS975..3053
Translation

Target ORF information:

RefSeq Version XM_017001320.1
Organism Homo sapiens(Human)
Definition Homo sapiens MPL proto-oncogene, thrombopoietin receptor (MPL), transcript variant X1, mRNA.

Target ORF information:

Epitope DYKDDDDK
Bacterial selection AMPR
Mammalian selection NeoR
Vector pcDNA3.1+/C-(K)DYK
XM_017001320.1

ORF Insert Sequence:

1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
901
961
1021
1081
1141
1201
1261
1321
1381
1441
1501
1561
1621
1681
1741
1801
1861
1921
1981
2041
ATGCCCTCCT GGGCCCTCTT CATGGTCACC TCCTGCCTCC TCCTGGCCCC TCAAAACCTG 
GCCCAAGTCA GCAGCCAAGG TGAGGTGCAC AGAGGGTGGA GATCACCTAT GCCCAGGAAG
AGGGAGCCCT GGGAGGTGAT GCAGGGCCCC GGGAGGGGAG GTAGAGTAAG AGGCTCTCCT
GCTGGTCCCC TCCCCTTCCA CATAAACATG CCTGGGAGGA CCCAGGGCCA ACTCACCAGC
TGTTCCTTAG ATGTCTCCTT GCTGGCATCA GACTCAGAGC CCCTGAAGTG TTTCTCCCGA
ACATTTGAGG ACCTCACTTG CTTCTGGGAT GAGGAAGAGG CAGCGCCCAG TGGGACATAC
CAGCTGCTGT ATGCCTACCC GCGGGAGAAG CCCCGTGCTT GCCCCCTGAG TTCCCAGAGC
ATGCCCCACT TTGGAACCCG ATACGTGTGC CAGTTTCCAG ACCAGGAGGA AGTGCGTCTC
TTCTTTCCGC TGCACCTCTG GGTGAAGAAT GTGTTCCTAA ACCAGACTCG GACTCAGCGA
GTCCTCTTTG TGGACAGTGT AGGCCTGCCG GCTCCCCCCA GTATCATCAA GGCCATGGGT
GGGAGCCAGC CAGGGGAACT TCAGATCAGC TGGGAGGAGC CAGCTCCAGA AATCAGTGAT
TTCCTGAGGT ACGAACTCCG CTATGGCCCC AGAGATCCCA AGAACTCCAC TGGTCCCACG
GTCATACAGC TGATTGCCAC AGAAACCTGC TGCCCTGCTC TGCAGAGGCC TCACTCAGCC
TCTGCTCTGG ACCAGTCTCC ATGTGCTCAG CCCACAATGC CCTGGCAAGA TGGACCAAAG
CAGACCTCCC CAAGTAGAGA AGCTTCAGCT CTGACAGCAG AGGGTGGAAG CTGCCTCATC
TCAGGACTCC AGCCTGGCAA CTCCTACTGG CTGCAGCTGC GCAGCGAACC TGATGGGATC
TCCCTCGGTG GCTCCTGGGG ATCCTGGTCC CTCCCTGTGA CTGTGGACCT GCCTGGAGAT
GCAGTGGCAC TTGGACTGCA ATGCTTTACC TTGGACCTGA AGAATGTTAC CTGTCAATGG
CAGCAACAGG ACCATGCTAG CTCCCAAGGC TTCTTCTACC ACAGCAGGGC ACGGTGCTGC
CCCAGAGACA GGTACCCCAT CTGGGAGAAC TGCGAAGAGG AAGAGAAAAC AAATCCAGGA
CTACAGACCC CACAGTTCTC TCGCTGCCAC TTCAAGTCAC GAAATGACAG CATTATTCAC
ATCCTTGTGG AGGTGACCAC AGCCCCGGGT ACTGTTCACA GCTACCTGGG CTCCCCTTTC
TGGATCCACC AGGCTGTGCG CCTCCCCACC CCAAACTTGC ACTGGAGGGA GATCTCCAGT
GGGCATCTGG AATTGGAGTG GCAGCACCCA TCGTCCTGGG CAGCCCAAGA GACCTGTTAT
CAACTCCGAT ACACAGGAGA AGGCCATCAG GACTGGAAGG TGCTGGAGCC GCCTCTCGGG
GCCCGAGGAG GGACCCTGGA GCTGCGCCCG CGATCTCGCT ACCGTTTACA GCTGCGCGCC
AGGCTCAACG GCCCCACCTA CCAAGGTCCC TGGAGCTCGT GGTCGGACCC AACTAGGGTG
GAGACCGCCA CCGAGACCGC CTGGATCTCC TTGGTGACCG CTCTGCATCT AGTGCTGGGC
CTCAGCGCCG TCCTGGGCCT GCTGCTGCTG AGGTGGCAGT TTCCTGCACA CTACAGGAGA
CTGAGGCATG CCCTGTGGCC CTCACTTCCA GACCTGCACC GGGTCCTAGG CCAGTACCTT
AGGGACACTG CAGCCCTGAG CCCGCCCAAG GCCACAGTCT CAGATACCTG TGAAGAAGTG
GAACCCAGCC TCCTTGAAAT CCTCCCCAAG TCCTCAGAGA GGACTCCTTT GCCCCTGTGT
TCCTCCCAGG CCCAGATGGA CTACCGAAGA TTGCAGCCTT CTTGCCTGGG GACCATGCCC
CTGTCTGTGT GCCCACCCAT GGCTGAGTCA GGGTCCTGCT GTACCACCCA CATTGCCAAC
CATTCCTACC TACCACTAAG CTATTGGCAG CAGCCTTGA

The stop codons will be deleted if pcDNA3.1+/C-(K)DYK vector is selected.

book

FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.
Annals of clinical and laboratory science46(6)592-600(2016 Dec)
Ebrahim EK,Assem MM,Amin AI,Kamel MM,El Meligui YM,Metwally AM


book

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Cancer discovery6(4)368-81(2016 Apr)
Elf S,Abdelfattah NS,Chen E,Perales-Patón J,Rosen EA,Ko A,Peisker F,Florescu N,Giannini S,Wolach O,Morgan EA,Tothova Z,Losman JA,Schneider RK,Al-Shahrour F,Mullally A


book

The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Experimental hematology35(11)1704-7(2007 Nov)
Hsiao HH,Yang MY,Liu YC,Lee CP,Yang WC,Liu TC,Chang CS,Lin SF


book

Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
Blood110(3)1077-9(2007 Aug)
Norton A,Fisher C,Liu H,Wen Q,Mundschau G,Fuster JL,Hasle H,Zeller B,Webb DK,O'Marcaigh A,Sorrell A,Hilden J,Gamis A,Crispino JD,Vyas P


book

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
British journal of haematology137(3)244-7(2007 May)
Guglielmelli P,Pancrazzi A,Bergamaschi G,Rosti V,Villani L,Antonioli E,Bosi A,Barosi G,Vannucchi AM,,


 
*
*
*
*